[1] Organisation for Economic Co-operation and Development. OECD
Health Data 2009: statistics and indicators for 30 countries. Paris:
OECD; 2009.
[2] World Health Organization. Promoting rational use of medicines:
core components – WHO Policy Perspectives on Medicines, No. 05.
Geneva: WHO Press; 2002.
[3] Ministerio de Sanidad y Consumo. Especialidades farmacéuticas
genéricas y medicamentos huérfanos. Información Terapéutica del
Sistema Nacional de Salud 2006;30:78–9.
[4] Okechukwu I, Bennett K, Feely J. General practitioners’ ranking of
evidence-based prescribing quality indicators: a comparative study
with a prescription database. British Journal of Clinical Pharmacology
2006;62:218–24.
[5] Federación Empresarial de Farmacéuticos Espa˜ noles. Observatorio
del medicamento y notas de prensa – Recopilatorio 2007. Madrid:
Federación Empresarial de Farmacéuticos Espa˜noles; 2008.
[6] Ajzen I. The theory of planned behaviour. Organizational Behavior
and Human Decision Processes 1991;50:179–211.
[7] Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a
systematic review of theoretical concepts, practical experience, and
research evidence in the adoption of clinical practice guidelines.
Canadian Medical Association Journal 1997;157:408–16.
[8] Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic
bullets: a systematic review of 102 trials of interventions to
improve professional practice. Canadian Medical Association Journal
1995;153:1423–31.
[9] Perkins MB, Jensen PS, Jaccard J, Gollwitzer P, Oettingen G, Pappadopulos
E, et al. Applying theory-driven approaches to understanding
and modifying clinicians’ behavior: what do we know? Psychiatric
Services 2007;58:342–8.
[10] US Public Health Service. Mental health: a report of the Surgeon General.
Washington, DC: Department of Health and Human Services;
1999.
[11] Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C,
Vernby A, et al. Pharmaceutical policies: effects of financial incentives
for prescribers. Cochrane Database of Systematic Reviews
2007;18:CD006731.
[12] De Vries H, Mudde AN, Dijkstra A, Willemsen MC. Differential
beliefs, perceived social influences, and self-efficacy expectations
among smokers in various motivational phases. Preventive Medicine
1998;27:681–9.
[13] DeVries H,MuddeAN. Predicting stage transitions for smoking cessation
applying the attitude social influence efficacy model. Psychology
& Health 1998;13:369–85.
[14] Bolman C, de Vries H, Mesters I. Factors determining cardiac nurses’
intentions to continue using a smoking cessation protocol. Heart &
Lung 2002;31:15–24.
[15] Bunce D, Birdi KS. The theory of reasoned action and theory of
planned behaviour as a function of job control. British Journal of
Health Psychology 1998;3:265–75.
[16] Edwards HE, Nash RE, Najman JM, Yates PM, Fentiman BJ, Dewar A,
et al. Determinants of nurses’ intention to administer opioids for pain
relief. Nursing & Health Sciences 2001;3:149–59.
[17] Limbert C, Lamb R. Doctors’ use of clinical guidelines: two applications
of the theory of planned behaviour. Psychology, Health and
Medicine 2002;7:301–10.
[18] Walker AE, Grimshaw JM, Armstrong EM. Salient beliefs and intentions
to prescribe antibiotics for patients with a sore throat. British
Journal of Health Psychology 2001;6:347–60.
[19] Rodríguez J, Prescripción de medicamentos genéricos y sus
determinantes psicosociales en facultativos de atención primaria
[dissertation]. Oviedo: Servicio de Publicaciones, Universidad de
Oviedo; 2006.
[20] de Vries H, Mesters I, Riet JV, Willems K, Reubsaet A. Motives of Belgian
adolescents for using sunscreen: the role of action plans. Cancer
Epidemiology, Biomarkers and Prevention 2006;15:1360–6.
[21] Broekhuizen K, van Poppel MN, Koppes LL, Brug J, van Mechelen
WA. Tailored lifestyle intervention to reduce the cardiovascular disease
risk of individuals with familial hypercholesterolemia (FH):
design of the PRO-FIT randomised controlled trial.BMCPublic Health
2010;15(10):69.
[22] Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What
are the obstacles to generic substitution? An assessment of the
behaviour of prescribers, patients and pharmacies during the first
year of generic substitution in Sweden. Pharmacoepidemiology Drug
and Safety 2005;14:341–8.
[23] Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards
and experiences of generic drug substitution in Norway. Pharmacy
World and Science 2006;28:284–9.
[24] Ping CC, Bahari MB, Hassali MA. A pilot study on generic medicine
substitution practices among community pharmacists in the State
of Penang, Malaysia. Pharmacoepidemiology Drug and Safety
2008;17:82–9.
[25] Ringuier R, Rouquette A, Dagorne C, Garnier F, Fanello S. Fifty
years old and more patients’ attitudes towards and experiences of
generic substitution of prescription medicines. Therapie 2008;63:
11–7.
[26] Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp
D, et al. The implications of choice: prescribing generic or
preferred pharmaceuticals improves medication adherence for
chronic conditions. Archives of Internal Medicine 2006;13(166):
332–7.
[27] Krusemark EA, Keith Campbell W, Clementz BA. Attributions, deception,
and event related potentials: an investigation of the self-serving
bias. Psychophysiology 2008;45:511–5.
[28] Vallès JA, Barreiro M, Cereza G, Ferro JJ, Martínez MJ, Escribà JM, et al.
A prospective multicenter study of the effect of patient education on
acceptability of generic prescribing in general practice. Health Policy
2003;65:269–75.
[29] Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a
systematic review. PLoS Medicine 2007;4:e283.
[30] Fowkes FG. Doctors’ knowledge of the costs of medical care. Medical
Education 1985;19:113–7.
[31] Wadland WC, Farquhar L, Priester F, Oberst K, Weismantel DP.
Increasing generic prescribing: a resident educational intervention.
Family Medicine 2005;37:259–64.
[32] World Health Organization. Guidelines on the use of International
Nonproprietary Names (INNs) for pharmaceutical substances.
Geneva: WHO Press; 1997. WHO/PHARM S/NOM 1570.
[33] Shrank WH, Stedman M, Ettner SL, DeLapp D, Dirstine J, Brookhart
MA, et al. Patient, physician, pharmacy, and pharmacy benefit design
factors related to generic medication use. Journal of General Internal
Medicine 2007;22:1298–304.
[34] Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O. Impact of pharmaceutical
promotion on prescribing decisions of general practitioners
in Eastern Turkey. BMC Public Health 2007;7:122.
[35] Figueiras A, Caama˜no F, Gestal Otero JJ. Incentives for doctors from
the pharmaceutical industry: ethical problems, limits, and alternatives.
Gaceta Sanitaria 1997;11:297–300.
[36] Muijrers PE, Grol RP, Sijbrandij J, Janknegt R, Knottnerus JA.
Differences in prescribing between GPs: impact of the cooperation
with pharmacists and impact of visits from pharmaceutical
industry representatives. Family Practice 2005;22:624–
30.
[37] Espigares Arroyo M, Montes Salas G, Altimiras Roset J, Iglesias
Sánchez JM, Brioso Jerez F. Predictive factors of drug prescription:
profile of the overprescribing physician. Gaceta Sanitaria
1994;8:25–9.
[38] Cummings SM, Savitz LA, Konrad TR. Reported response rates
to mailed physician questionnaires. Health Services Research
2001;35:1347–55.
[39] Servicio de Salud del Principado de Asturias (Gerencia). Recursos
humanos: características de los médicos de atención primaria.
Oviedo: Servicio de publicaciones, SESPA; 2006.